Cytotoxicity and DNA damage and repair in human lymphocytes exposed to three anticancer platinum drugs

Neoplasma

Volumn 46, Issue SUPPL. 1, 1999, Pages 61-63

  Blasiak J ^a   Kowalik, J ^a   Trzeciak, A ^a   Wojewodzka M ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF NUCLEAR CHEMISTRY AND TECHNOLOGY   (Poland)

Author keywords

Cisplatin; Comet assay; DNA damage; DNA repair; Genotoxic effects of anticancer drugs; Oxoplatin

Indexed keywords

EID: 0041962606     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. ABRAMS, M.J., MURRER, B.A.: Metal compounds in therapy and diagnosis. Science, 257, 1993, 725-730.
2. BALDEW, G.S, MC VIE, J.G., VAN DER VALK, M.A., LOS, G., DE GOEIJ, J.J., VERMEULEN, N.P.: Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen. Cancer Res., 50, 1990, 7031-7036.
3. BALDEW, G.S., MOL, J.G.J., DE KANTER, F.J.J., VAN BAAR, B., DE GOEIJ, J.J.M., VERMEULEN, N.P.E.: The mechanism of interaction between cisplatin and selenite. Biochem. Pharmacol., 41, 1991, 1429-1437.
4. BARNHART, K.M., BOWDEN, G.T.: Cisplatin as an initiating agent in two-stage mouse skin carcinogenesis. Cancer. Lett., 29, 1985, 101-105.
5. BERNAL-MENDEZ, E., BOUDVILLAN, M., GONZALEZ-VILCHEZ, E, LENG, M.: Chemical versatility of transplatin monofunctional adducts within multiple site-specifically platinated DNA. Biochemistry, 36, 1997, 7281-7287.
6. BÜNING, H., ALTMAN, J., BECK, W., ZORBAS, H.: Molecular interaction of DNA with bisplatinum(II) complexes having bis(vicinal 1,2-diamines) as ligand. Biochemistry, 36, 1997, 11408-11418.
7. L- trans) 1,2-diaminocyclohexane-platinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721 ), or sodium selenite in the Fischer 344 rat. Fundam. Appl. Toxicol., 14, 1990, 706-719.
8. COMBS, G.F., GRAY, W.P.: Chemopreventive agents: selenium. Pharmacol. Then, 79, 1998, 179-192.
9. FERGUSON, L.R., PEARSON A.E.: The clinical use of mutagenic anticancer drugs. Mutat. Res., 355, 1996, 1-12.
10. [ 10] FICHTINGER-SCHEPMAN, A.M.J., VAN DER VEER, J.L., DEN HARTOG, J.H.J., LOHMAN, P.H.M., REEDIJK, J.: Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry, 24, 1985, 707-713.
11. FICHTINGER-SCHEPMAN, A.M.J., VAN OOSTEROM , A.T., LOHMAN, P.H.M., BERENDS, F.: Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer. Res., 47, 1987, 3000-3004.
12. JOHNSON, N.P., BUTOUR, J-L.,VILIANI, G., WIMMER, F.L., DEFAIS, M., PIERSON, V., BRABEC, V.: Metal antitumor compounds: the mechanism of action of platinum complexes. Progr. Clin. Biochem. Med., 10, 1989, 1-24.
13. KEMPF, S.R., IVANKOVIC, S.: Carcinogenic effect of cisplatin (cisdiamminedichloroplatinum(II), CDDP) in BD IX rats. J. Cancer Res. Clin. Oncol., 111, 1986, 133-136.
14. LEOPOLD, W.R., MILLER, B.C., MILLER, J.A.: Carcinogenicity of antitumor cis-platinum(II) coordination complexes in mouse and rat. Cancer Res., 39, 1979, 913-918.